Vermillion and Roth Capital Partners to Host Group Conference Call
Monday April 19, 11 AM Pacific/2 PM Eastern
FREMONT, Calif., April 8 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRML) today announced that it will be participating in a conference call hosted by Roth Capital Partners and Matt Dolan, Senior Research Analyst, Medical Devices. Gail Page, Chief Executive Officer, and Eric Fung, MD, PHD, Senior Vice President and Chief Scientific Officer of Vermillion, Inc. will be presenting an overview of the company and its product OVA1™.
The presentation is scheduled for Monday, April 19, 2010 at 11 AM Pacific/2 PM Eastern. Please contact Roth Capital Partners for dial in information.
About the OVA1 Test
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
SOURCE Vermillion, Inc.
Share this article